Factors Associated with Uterine Fibroids among Women of Reproductive Age in La-ngu District, Satun Province
Article Sidebar
Main Article Content
Abstract
Background: The situation of Uterine fibroid patients in La-ngu District, Satun Province, from 2019 to 2022 revealed a total of 88 cases, with a continuously increasing trend in incidence rates. Therefore, the researcher is interested in studying the factors associated with the occurrence of uterine tumors among women of reproductive age in La-ngu District, Satun Province.
Methods: This research was a case-control study conducted among patients with uterine fibroids in La-ngu District, Satun Province. Data were retrospectively collected over four years, from 2019 to 2022. The study sample consisted of 176 individuals aged 18 years and older (88 in the case group and 88 in the control group), selected using simple random sampling. Data were collected using an interview questionnaire, which had a content validity index (CVI) of 0.89 and a reliability coefficient of 0.81. The statistical methods used included percentages, means, standard deviations, medians, interquartile ranges, and logistic regression analysis. The statistical significance level was set at 0.05.
Results: The patients had a mean age of 47 years (SD=7.5). Approximately 60.2% had completed primary education. About 58.3% had used oral contraceptive pills for more than six years. Around 43.1% had 3–5 children. Approximately 36.4% had a body mass index (BMI) classified as Level 1 obesity. Menstrual abnormalities were observed in 38.6% of the patients. Factors found to be statistically significantly associated with the occurrence of uterine fibroids included: age between 45 and 64 years (AOR=2.9; p=0.010), menstrual abnormalities (AOR=5.0; p=0.003), menorrhagia (heavy menstrual bleeding) (AOR = 9.6; p <0.001), abdominal pain (AOR=2.9; p=0.014), and diastolic blood pressure (AOR=1.1; p=0.004).
Conclusions: The occurrence of Uterine Fibroids was found to be significantly higher among patients with menstrual abnormalities, heavy menstrual bleeding, and abdominal pain. Health agencies should continuously provide education and conduct proactive and comprehensive disease screening.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Gofur N, Gofur A, Soesilaningtyas GA, Kahdina M, Putri HJCO. Uterine myoma, risk factor, and pathophysiology: a review article. Clin Onco. 2021;4(3):1-4.
Wallach EE, Vlahos NFJO, Gynecology. Uterine myomas: an overview of development, clinical features, and management. Obstetrics & Gynecology. 2004;104(2):393-406.
Bernard G, Darai E, Poncelet C, Benifla J-L, Madelenat PJEJoO, Gynecology, et al. Fertility after hysteroscopic myomectomy: effect of intramural myomas associated. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2000;88(1):85-90.
Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JTJBMJ. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293(6543):359-62.
Baird DDJAjoe. Invited commentary: uterine leiomyomata—we know so little but could learn so much. American journal of epidemiology. 2004;159(2):124-6.
Takahashi N, Yoshino O, Hiraike O, Maeda E, Nakamura M, Hori M, et al. The assessment of myometrium perfusion in patients with uterine fibroid by arterial spin labeling MRI. Springerplus. 2016;5:1-7.
Sarkar MK, Halder A, Chowdhury SJIJoPHR, Development. A Study to Find Out the Association of Vitamin D Levels with Leiomyoma Uterus. Indian Journal of Public Health Research & Development. 2020;11(9).
Marques MC, Santos V, Pereira JSJAOGP. Uterine fibroid: size does matter Mioma uterino: porque o tamanho importa. Acta Obstet Ginecol Port. 2022;16(1):66-7.
All ansary MA, abd el megeed Aemi. Level of Vitamin D3 in Women Who Have Uterine Fibroids. J Evidence Based Women's Health Journal. 2021;11(2):99-106.
Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environmental health perspectives. 2003;111(8):1037-54.
Sabry M, Al-Hendy A. Medical Treatment of Uterine Leiomyoma. Reproductive sciences. 2012;19(4):339-53.
Cheng L-C, Li H-Y, Gong Q-Q, Huang C-Y, Zhang C, Yan J-ZJFiM. Global, regional, and national burden of uterine fibroids in the last 30 years: Estimates from the 1990 to 2019 Global Burden of Disease Study. Frontiers in Medicine. 2022;9:1003605.
Lui K-JJAjoe. Estimation of sample sizes in case-control studies with multiple controls per case: dichotomous data. American journal of epidemiology. 1988;127(5):1064-70.
Suresh KP, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. Journal of Human Reproductive Sciences. 2012;5(1):7-13.
Moss N, Benditt EJTAjop. Human atherosclerotic plaque cells and leiomyoma cells. Comparison of in vitro growth characteristics. The American journal of pathology. 1975;78(2):175.
Boynton-Jarrett R, Rich-Edwards J, Malspeis S, Missmer SA, Wright R. A Prospective Study of Hypertension and Risk of Uterine Leiomyomata. American Journal of Epidemiology. 2005;161(7):628-38.
Vannuccini S, Clemenza S, Cassioli E, Rossi E, Castellini G, Ricca V, et al. Uterine fibroids, perceived stress, and menstrual distress: a key role of heavy menstrual bleeding. Reproductive Sciences. 2023;30(5):1608-15.
BS. Modern management of uterine fibroids. Acta Obstetricia et Gynecologica Scandinavica. 2008;87(8):812-23.
